Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Repare Therapeutics Inc. (RPTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results Presented initial camonsertib-PARPi combination Phase 1/2 clinical data at AACR 2023 demonstrating durable clinical benefit across tumor types, genomic alterations, PARPi choice or platinum resistance Roche has included a camonsertib-based arm in its Phase 2 TAPISTRY study and its Phase 1/2 Morpheus Lung study of multiple combinations in metastatic non-small cell lung cancer Reported clinical proof of concept for lunresertib in June 2023 including achievement of monotherapy safety and tolerability primary endpoints and identification of two proposed dose/schedules Presented early lunresertib combination response data in June 2023, and expects to present further Phase 1 MYTHIC Module 2 data at a m..."
05/09/2023 8-K Quarterly results
Docs: "Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results Reported initial camonsertib data from ongoing Phase 1/2 TRESR and Phase 1b/2 ATTACC clinical trials in a plenary oral presentation at 2023 AACR Annual Meeting Camonsertib combination therapy showed 48% CBR across tumor types regardless of choice of PARP inhibitor or platinum resistance, with a favorable safety and tolerability profile Company on track to report initial RP-6306 monotherapy data from Phase 1 MYTHIC clinical trial in June 2023 Announced the appointment of Susan Molineaux, Ph.D., and departure of Jerel Davis, Ph.D. on our Board of Directors, as well as the addition of Daniel Belanger to the senior leadership team CAMBRIDGE, Mass. & MONTREAL —May 9, 2023"
11/09/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
Docs: "Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results Cambridge, MA & Montreal, QC, March 1, 2022 -- Repare Therapeutics Inc. , a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2021. “We achieved several key milestones in 2021 to advance our innovative, synthetic lethality-based pipeline across multiple clinical programs,” said Lloyd M. Segal, President and Chief Executive Officer of Repare. “We are particularly pleased with important progress in our RP-3500 program and to have initiated our second clinical program..."
11/10/2021 8-K Quarterly results
Docs: "Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results Oral presentation of initial data from the Phase 1/2 TRESR trial at the AACR-NCI-EORTC conference Results demonstrated favorable and differentiated safety profile, along with promising early activity, for RP-3500 in patients with a range of synthetic-lethal genomic alterations Gross Proceeds of $101.2 Million Raised in Upsized Follow-on Public Offering Thomas Civik appointed to Board of Directors as new Chairman Cambridge, MA & Montreal, QC, November 10, 2021 -- Repare Therapeutics Inc. , a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the third q..."
08/12/2021 8-K Quarterly results
Docs: ", August 12, 2021 -- Repare Therapeutics Inc. , a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2021."
03/04/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Advanced CCNE-1 synthetic lethal inhibitor program into Good Laboratory Practice toxicology studies ahead of original timeline. The Company anticipates initiating a Phase 1 clinical trial for RP-6306 in the third quarter of 2021, which is ahead of its original guidance of an IND filing in the second half of 2021. • Initiated a Phase 1/2 clinical trial evaluating RP-3500 as a monotherapy and in combination with Pfizer's PARP inhibitor, talazoparib, in patients with solid tumors. In July 2020, the Company began dosing in a Phase 1/2 clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR for the treatment of solid tumors in patients with specific genome instability-related genetic alterations, including those in the ATM gene . RP-3500 will be evaluated a..."
08/13/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy